Article info
Letter
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
- Correspondence to Dr Larissa Mulka, Department of Sexual Health and HIV, Royal Sussex County Hospital, Brighton, East Sussex BN2 5BE, UK; larissa.mulka{at}bsuh.nhs.uk
Citation
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
Publication history
- Received August 4, 2015
- Accepted August 6, 2015
- First published February 18, 2016.
Online issue publication
May 13, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/